Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients

Česká verzia

Authors: Zdeněk Adam ¹; Eva Ozábalová ²; Petr Němec ³; Helena Bedáňová ³; Milan Kuman ³; Jan Krejčí ²; Lenka Špinarová ²; Víta Žampachová ⁴; Zdeňka Čermáková ⁵; Luděk Pour ¹; Marta Krejčí ¹; Viera Sanecká ¹; Martin Štork ¹; Tomáš Pika ⁶; Jan Straub ⁷; Dagmar Adamová ⁸; Yvetta Stavařová ⁹; Zdeněk Král ¹; Jiří Mayer ¹
Authors place of work: Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice ¹; I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně ²; Centrum kardiovaskulární a transplantační chirurgie, Brno ³; I. patologicko-anatomický ústav LF MU a FN u sv. Anny v Brně ⁴; Oddělení klinické biochemie FN Brno, pracoviště Bohunice ⁵; Hemato-onkologická klinika LF UP a FN Olomouc ⁶; I. interní klinika – klinika hematologie 1. LF UK a VFN v Praze ⁷; Hematologicko-transfúzní oddělení Slezské nemocnici v Opavě, p. o. ⁸; Hematologicko-transfuzní oddělení Krajské nemocnice T. Bati, a. s., Zlín ⁹
Published in the journal: Vnitř Lék 2018; 64(4): 441-449
Category: Case Reports

Summary

The prognosis for patients with cardiac impairment due to AL-amyloid deposition and severe cardiac insufficiency is poor, with a survival median in the order of months. The classical treatment of AL-amyloidosis in combination with cardiac insufficiency is very poorly tolerated and the treatment of such patients is associated with considerably higher mortality than among other patients with AL-amyloidosis. If, however, patients with an isolated or another dominating cardiac impairment, without severe damage to other organs and tissues, have a heart transplant performed, their cardiovascular condition will significantly improve as a result, along with their ability to tolerate any kind of treatment for AL-amyloidosis including that using high-dose chemotherapy with a transplant of autologous hematopoietic stem cells. The achievement of complete remission of AL-amyloidosis is a precondition for long-term survival, since when not achieved, amyloid deposition also arises in the transplanted heart. At the Centre for Cardiovascular and Transplantation Surgery, Brno, the first heart transplant due to its impairment by AL-amyloidosis was performed in 2010. By the year 2017 the number of patients with AL-amyloidosis, who had first undergone a heart transplant with subsequent treatment for AL-amyloidosis, increased to 5. The median age at which a heart transplant was performed is 60 (48–65) years. Four patients were men, one was a woman. The median monitoring equals 65 (88–15) months. Complete remission of AL-amyloidosis was achieved in all the patients. There were 5 lines of treatment needed for the first patient to attain it, of that twice high-dose melphalan with autologous stem cell transplantation, for the second patient a second-line treatment, high-dose melphalan and bortezomib-based therapy. No specific therapy was needed for the third patient, as immunosuppressive therapy following the heart transplant containing prednison led to complete remission of AL-amyloidosis. In the fourth case, sustainable complete remission was reached by high-dose melphalan and in the fifth case by one line of bortezomib-based therapy. The aforementioned data illustrate that a heart transplant is the first step which makes the patients with a severe heart failure, not tolerating any efficient therapy of AL-amyloidosis, capable of undergoing intense treatment of AL-amyloidosis. Sometimes one high-dose chemotherapy is sufficient, while at other times multiple treatment lines are needed to reach complete remission of AL-amyloidosis.

Key words:
AL-amyloidosis – autologous hematopoietic stem cells transplantation – bortezomib – cardiomyopathy – lenalidomide – thalidomide – heart transplantation

Zdroje

1. Ščudla V, Pika T, Minařík J Role vyšetření heavy/light chain párů imunoglobulinů u monoklonálních gamapatií. Vnitř Lék 2015; 61(1): 60–61, 63–71.

2. Ščudla V, Adam Z,Hájek R et al. Souhrn doporučení 2013 „Diagnostika a léčba systémové AL amyloidózy“. Transfuze Hematol Dnes 2013; 19(Suppl 5): 7–12.

3. Pika T, Lochman P, Vymětal J et al. Přínos vyšetření kardiálních biomarkerů pro stratifikaci a sledování pacientů s AL-amyloidózou. Vnitř Lék 2013; 59(9): 776–781.

4. Kuchyňka P, Paleček T, Šimek S et al. Izolovaná forma kardiální amyloidózy. Vnitř Lék 2008; 54(10): 1010–1013.

5. Danzig V, Danzigová Z, Lukás K et al. Primární postižení kardiorespiračního systému AL-amyloidózou. Vnitř Lék 1994; 40(2): 104–107.

6. Kováčik F, Táborská M, Hutyra M et al. Srdeční amyloidóza. Kazuistika. Interv Akut Kardiol 2016; 15(3): 145–147.

7. Látalová P, Pika T, Flodr P. AL-amyloidóza v obrazech. Transfuze Hematol Dnes 2014; 20(3): 76–80.

8. Honsová E. Jak v praxi zlepšit diagnostiku systémových amyloidóz. Cesk Patol 2009; 45–54(3): 85–87.

9. Pika T, Vymětal J, Metelka R et al. Postižení srdce při Al-amyloidóze. Interní Med 2008; 10(10): 466–469.

10. Kociánová E, Václavík J, Táborský M et al. Amyloidóza jako vzácná příčina dušnosti. Cor Vasa 2010; 52(3): 188–192.

11. Flodrová P, Pika T, Flodr P. Vyšetření tkání při diagnostice amyloidu. Transfuze Hematol Dnes 2016; 22(Suppl 1): S1213-S1214.

12. Krejčí J, Hude P, Špinarová L et al. Transplantace srdce indikace, komplikace – naše zkušenosti se sledováním 100 pacientů po srdeční transplantaci. Vnitř Lék 2000; 46(11): 750–755.

13. Pika T, Lochman P, Vymětal J et al. Dosažení kompletní hematologické remise je podstatné pro dlouhodobé přežití u pacientů s AL-amyloidózou s postižením srdce. Klin Onkol 2013; 26(5): 343–347.

14. Tichý M, Maisnar V. Laboratorní identifikace monoclonalnálního immunoglobinu. Vnitř Lék 2006; 52(Suppl 2): 41–45.

15. Adam Z, Krejčí J, Krejčí M at al. Transplantace srdce a následná léčba AL-amyloidózy. Vnitř Lék 2013; 59(2): 136–147.

16. Kastritis E, Dimopoulos MA. Prognosis and risk assessment in AL amyloidosis – state of the art. Amyloid 2011; 18(Suppl 1): 89–91. Dostupné z DOI: <http://dx.doi.org/10.3109/13506129.2011.574354032>. Erratum in Amyloid 2011; 18(Suppl 1):91.

17. Mekinian A, Lions C, Leleu X et al. [Amyloidosis Study Group]. Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging. Am J Med 2010; 123(9): 864–868. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2010.03.022>.

18. Kristen AV, Giannitsis E, Lehrke S et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010; 116(14): 2455–2461. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2010–02–267708>.

19. Kumar SK, Dispenzieri A, Lacy MQ et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 2011; 86(3): 251–255. Dostupné z DOI: <http://dx.doi.org/10.1002/ajh.21948>.

20. Kumar S, Dispenzieri A, Lacy MQ et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30(9): 989–995. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2011.38.5724>.

21. Dispenzieri A, Gertz M, Kyle A et al. Serum cardiac troponins and N-terminal Pro-Brain Natriuretic Peptide: A staging system for primary AL-amyloidosis. J Clin Oncol 2004; 22(18): 3751–3757. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2004.03.029>.

22. Wechalekar AD, Schonland SO, Kastritis E et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121(17): 34203427. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2012–12–473066>.

23. Guan J, Mishra S, Shi J et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol 2013; 108(5): 378–378. Dostupné z DOI: <http://dx.doi.org/10.1007/s00395–013–0378–5>.

24. Cordes S, Dispenzieri A, Lacy MQ et al. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis. Cancer 2012; 118(24): 6105–6109. Dostupné z DOI: <http://dx.doi.org/10.1002/cncr.27660>.

25. Karafiatova L, Pika T. Amyloid cardiomyopathy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2017; 161(2): 117–127. Dostupné z DOI: <http://dx.doi.org/10.5507/bp.2017.001>.

26. Paleček T, Horák J, Kuchyňka P et al. Restriktivní kardiomyopatie na podkladě AL-amyloidózy. Kapitoly z kardiologie pro praktické lékaře 2012; 4(3): 112–113.

27. Zemánek D, Linhartová K. Není hypertrofie jako hypertrofie aneb nezapomínejme na amyloidózu. Kardiol Rev Int Med 2011; 13(4): 228–232.

28. Selvanayagam JB, Hawkins PN, Paul B et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007; 50(22): 2101–2110. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2007.08.028>. Erratum in J Am Coll Cardiol. 2011; 57(13): 1501.

29. DePasquale EC, Nasir K, Jacoby DL. Outcomes of adults with restrictive cardiomyopathy after heart transplantation. J Heart Lung Transplant 2012; 31(12): 1269–1275. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2012.09.018>.

30. Linhartová K. Diagnostika a léčba nejčastější formy restriktivní kardiomyopatie: srdeční amyloidózy. Cor Vasa 2010; 52(7–8): 393–396.

31. Dubrey SW, Burke MM, Hawkins PN et al. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant 2004; 23(10): 1142–1153. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2003.08.027>.

32. Gillmore JD, Goodman HJ, Lachmann HJ et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006; 107(3): 1227–1229. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2005–08–3253>.

33. Mehra MR, Canter CE, Hannan MM et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 2016; 35(1): 1–23. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2015.10.023>.

34. Kristen AV, Sack FU, Schonland SO et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail 2009; 11(10): 1014–1020. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjhf/hfp121>.

35. Mignot A, Varnous S, Redonnet M et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis 2008; 101(9): 523–532. Dostupné z DOI: <http://dx.doi.org/10.1016/j.acvd.2008.06.018>.

36. Lacy MQ, Dispenzieri A, Hayman SR et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant 2008; 27(8): 823–829. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2008.05.016>.

37. Roig E, Almenar L, Gonzalez-Vilchez F et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant 2009; 9(6): 1414–1419. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1600–6143.2009.02643.x>.

38. Sattianayagam PT, Gibbs SD, Pinney JH et al. Solid organ transplantation in AL amyloidosis. Am J Transplant 2010; 10(9): 2124–2131. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1600–6143.2010.03227.x>.

39. Dey BR, Chung SS, Spitzer TR et al. Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation 2010; 90(8): 905–911. Dostupné z DOI: <http://dx.doi.org/10.1097/TP.0b013e3181f10edb>.

40. Varr BC, Liedtke M, Arai S et al. Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies. J Heart Lung Transplant 2012; 31(3): 325–331. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2011.09.010>.

41. Estep JD, Bhimaraj A, Cordero-Reyes AM et al. Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management. Methodist Debakey Cardiovasc J 2012; 8(3): 8–16.

42. Gilstrap L, Niehaus E, Malhotra R et al. Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis. J Heart Lung Transplant 2014; 33(2): 149–156. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2013.09.004>.

43. Grogan M, Gertz M, McCurdy A et al. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience. World J Transplant 2016; 6(2): 380–388. Dostupné z DOI: <http://dx.doi.org/10.5500/wjt.v6.i2.380>.

44. Davis MK, Kale P, Liedtke M et al. Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. Am J Transplant 2015; 15(3): 650–658. Dostupné z DOI: <http://dx.doi.org/10.1111/ajt.13025>.

45. Paleček T, Fikrle T, Němeček E et al. Contemporary treatment of amyloid heart disease. Current pharmaceutical design 2015; 21(4): 491–506.

46. Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis. A consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol 2005; 79(4): 319–328. Dostupné z DOI: <http://dx.doi.org/10.1002/ajh.20381>.

47. Gertz MA, Merlini G. Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid 2010; 17(Suppl 1): 48–49.

48. Van Gameren I, van Rijswijk MH, Bijzet J et al. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 2009; 94(8): 1094–1100. Dostupné z DOI: <http://dx.doi.org/10.3324/haematol.2008.004119>.

49. Sanchorawala V, Seldin DC, Magnani B et al. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005; 36(7): 597–600. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.bmt.1705106>.

50. Adam Z, Štork, M, Pour L et al. Výsledky léčby AL-amyloidózy režimy obsahujícími bortezomib, dexametazon a dále cyklofosfamid anebo doxorubicin. Vnitř Lék 2012; 58(12): 896–904.

51. Adam Z, Matýšková M, Krejčí M et al. Pacientka s AL-amyloidózou a závažným deficitem faktoru X je po vysokodávkované chemoterapii již 7 let v kompletní hematologické remisi s normální aktivitou faktoru X. Popis případu a přehled literatury. Vnitř Lék 2010; 56(1): 67–78.

52. Fikrle M, Palecek T, Mašek M et al. The diagnostic performance of cardiac magnetic resonance in detection of myocardial involvement in AL amyloidosis. Clin Physiol Funct Imaging 2016; 36(3): 218–224. Dostupné z DOI: <http://dx.doi.org/10.1111/cpf.12216>.

53. Fikrle M, Kuchyňka P, Mašek M et al. Přínos magnetické rezonance pro diagnostiku kardiomyopatií a myokarditidy. Vnitř Lék 2016; 62(12): 976–984.